SCHEMBL21777835

SCHEMBL21777835

N[C@@H]1C2CC[C@H]1CN(Cc1ccccc1)C2

nearest known ligand 0.69

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FUCA1 P04066 2/20 0.53
SIGMAR1 Q99720 1/20 0.50
DRD2 P14416 1/20 0.49
DRD3 P35462 1/20 0.49
ACHE P22303 3/20 0.49
BCHE P06276 2/20 0.49
BACE1 P56817 2/20 0.49
GRIN2B Q13224 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CCR3 P51677 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21777836 1.00 FUCA1 (0.53) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL2844733 1.00 FUCA1 (0.53) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL2844736 1.00 FUCA1 (0.53) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL21773216 1.00 FUCA1 (0.53) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL21777837 1.00 FUCA1 (0.53) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL21777260 1.00 FUCA1 (0.53) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL21773211 1.00 FUCA1 (0.53) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL6616536 0.93 FUCA1 (0.50) FUCA1SIGMAR1DRD2DRD3ACHE
SCHEMBL5071734 0.90 ACHE (0.55) SIGMAR1DRD2DRD3ACHEBCHE
SCHEMBL4090277 0.89 KDM1A (0.54) FUCA1SIGMAR1DRD2DRD3ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3844158-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS Xenon Pharmaceuticals Inc. (CA) 2021-07-07 EP disclosed
WO-2020047312-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 WO disclosed